N- and O-Glycans Modulate Galectin-1 Binding, CD45 Signaling, and T Cell Death*
- From the Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095
- ↵1 To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, UCLA School of Medicine, 10833 LeConte Ave, Los Angeles, CA 90095. Tel.: 310-206-5985; Fax: 310-206-0657; E-mail: lbaum{at}mednet.ucla.edu.
Abstract
Galectin-1, a β-galactoside-binding protein highly expressed in the thymus, induces apoptosis of specific thymocyte subsets and activated T cells. Galectin-1 binds to N- and O-glycans on several glycoprotein receptors, including CD7, CD43, and CD45. Here we show that galectin-1 signaling through CD45, which carries both N- and O-glycans, is regulated by CD45 isoform expression, core 2 O-glycan formation and the balance of N-glycan sialylation. Regulation of galectin-1 T cell death by O-glycans is mediated through CD45 phosphatase activity. While galectin-1 signaling in cells expressing low molecular weight isoforms of CD45 requires expression of core 2 O-glycans (high affinity ligands for galectin-1), galectin-1 signaling in cells expressing a high molecular weight isoform of CD45 does not require core 2 O-glycans, suggesting that a larger amount of core 1 O-glycans (low affinity ligands for galectin-1) is sufficient to overcome lack of core 2 O-glycans. Furthermore, regulation of galectin-1 signaling by α2,6-sialylation of N-glycans is not solely dependent on CD45 phosphatase activity and can be modulated by the relative expression of enzymes that attach sialic acid in an α2,6- or α2,3-linkage. Thus, N- and O-glycans modulate galectin-1 T cell death by distinct mechanisms, and different glycosylation events can render thymocytes susceptible or resistant to galectin-1.
- Apoptosis
- Carbohydrate/Glycoprotein
- Cell/Apoptosis
- Glycoproteins/Carbohydrates
- Glycosylation
- Phosphorylation/Phosphatases/Tyrosine
- Tissue/Organ Systems/Leukocyte/Lymphocyte
Footnotes
-
↵* This work was supported, in whole or in part, by National Institutes of Health Grant GM63281 (to L. G. B.) and National Institutes of Health Training Grant T32 AI52031 (to L. A. E.). This work was also supported by a grant from the University of California, Cancer Research Coordinating Committee (to L. G. B.).
-
↵
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.
- Received September 14, 2009.
- Revision received November 9, 2009.
- © 2010 by The American Society for Biochemistry and Molecular Biology, Inc.











